Literature DB >> 21565238

T-cell immunoglobulin and mucin domain 3 genetic polymorphisms are associated with rheumatoid arthritis independent of a shared epitope status.

Yeong Wook Song1, Churl Hyun Im, Jae Hee Park, Yun Jong Lee, Eun Young Lee, Eun Bong Lee, Kyungsook Park.   

Abstract

The aim of this study was to investigate T-cell immunoglobulin and mucin domain 3 (TIM3) genetic polymorphisms and rheumatoid arthritis (RA) according to the shared epitope (SE) status. Six single nucleotide polymorphisms (SNPs: rs11742259 [C/T], rs10515746 [C/A], rs35960726 [A/G], rs1036199 [A/C], rs4704846 [A/G], and rs11134551 [A/G]) in the TIM3 gene from 366 RA patients and 389 healthy controls were investigated using the real-time polymerase chain reaction method. Associations between these SNPs and clinical manifestations (including SE status) were investigated using the SPSS program and Haploview. Polymorphisms of rs35690726 (AG+ GG vs AA: 8.2% vs 1.8%, p(c) < 0.001) were significantly associated with RA with or without SE (p(c) < 0.001 or p(c) = 0.009, respectively). Polymorphisms of rs11742259 (p(c) = 0.003) and rs1036199 (p(c) = 0.012) were significantly different in RA patients with SE, but not in those without SE. In haplotype analysis with a permutation test for the first 4 SNPs (rs11742259, rs10515746, rs35690726, and, rs1036199), CCAA, CCGA, CCGC, and CAAA haplotypes were significantly associated with RA. The clinical characteristics of RA patients were not significantly associated with any TIM3 polymorphism. TIM3 genetic polymorphisms may have a role in the development of RA regardless of a shared epitope status.
Copyright © 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565238     DOI: 10.1016/j.humimm.2011.04.007

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  11 in total

Review 1.  TIM polymorphisms--genetics and function.

Authors:  J Lee; B Phong; A M Egloff; L P Kane
Journal:  Genes Immun       Date:  2011-11-03       Impact factor: 2.676

Review 2.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 3.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

4.  Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study.

Authors:  Zheng Wang; Xinghan Liu; Xijing Wang; Tie Chong; Shuai Lin; Meng Wang; Xiaobin Ma; Kang Liu; Peng Xu; Yanjing Feng; Zhijun Dai
Journal:  Oncotarget       Date:  2016-07-12

Review 5.  Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.

Authors:  Hwei-Fang Tsai; Ping-Ning Hsu
Journal:  J Biomed Sci       Date:  2017-05-25       Impact factor: 8.410

6.  TIM family gene polymorphism and susceptibility to rheumatoid arthritis: Systematic review and meta-analysis.

Authors:  Bahman Razi; Samira Esmaeili Reykandeh; Shahab Alizadeh; AliAkbar Amirzargar; Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

7.  TIM-3 genetic variants and risk of Behçet disease in the Iranian population.

Authors:  Mitra Ataei; Farinaz Behfarjam; Zohreh Jadali
Journal:  An Bras Dermatol       Date:  2019-10-17       Impact factor: 1.896

Review 8.  Tim-3 expression and its role in hepatocellular carcinoma.

Authors:  Feifei Liu; Yanning Liu; Zhi Chen
Journal:  J Hematol Oncol       Date:  2018-10-11       Impact factor: 17.388

9.  TIM-3 rs1036199 polymorphism increases susceptibility to autoimmune diseases: evidence based on 4200 subjects.

Authors:  Rongzeng Liu; Xing Wang; Xiafei Chen; Shengnan Wang; Heqian Zhang
Journal:  Biosci Rep       Date:  2018-11-23       Impact factor: 3.840

10.  TIM-3 Genetic Variants Are Associated with Altered Clinical Outcome and Susceptibility to Gram-Positive Infections in Patients with Sepsis.

Authors:  Caspar Mewes; Tessa Alexander; Benedikt Büttner; José Hinz; Ayelet Alpert; Aron-F Popov; Michael Ghadimi; Tim Beißbarth; Mladen Tzvetkov; Marian Grade; Michael Quintel; Ingo Bergmann; Ashham Mansur
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.